Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768451 | 0.79 | NPSR1 (0.47) | NPSR1TDP1PKMHPGDPOLB | |
| SCHEMBL2768496 | 0.77 | KDR (0.43) | POLBMAPTALDH1A1LMNAKDM4E | |
| SCHEMBL2768537 | 0.76 | KDR (0.49) | NPSR1HPGDPOLBMAPTSMN1; SMN2 | |
| SCHEMBL2769349 | 0.72 | ALDH1A1 (0.47) | NPSR1TDP1PKMHPGDPOLB | |
| SCHEMBL4339183 | 0.67 | HPGD (0.48) | NPSR1TDP1HPGDPOLBMAPT | |
| SCHEMBL4342267 | 0.67 | HPGD (0.50) | NPSR1TDP1PKMHPGDPOLB | |
| SCHEMBL7125716 | 0.66 | HPGD (0.56) | NPSR1TDP1PKMHPGDPOLB | |
| SCHEMBL4239974 | 0.66 | HPGD (0.56) | NPSR1TDP1HPGDPOLBMAPT | |
| SCHEMBL4341196 | 0.66 | MEN1 (0.49) | NPSR1TDP1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL2770623 | 0.66 | KDR (0.56) | HPGDPOLBMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1479670-B1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| EP-1479670-B1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-7390797-B2 | Fused indazole compounds | EISAI CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390797-B2 | Fused indazole compounds | EISAI CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-7390797-B2 | Fused indazole compounds | EISAI CO., LTD. (JP) | 2008-06-24 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060111419-A1 | Novel fused indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1479670-A1 | NOVEL FUSED RING INDAZOLE COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111419-A1 | Novel fused indazole compounds | MAP2K3, MAP3K11, MAP2K2 | NPSR1 3408/4885TDP1 3834/4885PKM 3185/4885 |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | NPSR1 4377/4885TDP1 2473/4885PKM 1290/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | NPSR1 4377/4885TDP1 2473/4885PKM 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.